Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A Breast Cancer Biomarker Point of CarePOCDiagnostic Platform Integrating Dual-Functionalized Nanoparticle for Magnetic Gradient Ranking and Electrochemical Sensing

Project description

Innovative point-of-care platform for early breast cancer detection

Breast cancer is the most prevalent neoplasm and the second leading cause of cancer-related mortality in women worldwide. The EU-funded Biochip-images project will strive to improve early cancer detection via the development of a point-of-care (POC) device for biomarker detection by employing a combination of magnetophoresis, electroanalysis, nanotechnology, and microfluidic integration. The objectives of the project include the development of dual-nanoparticles with immunological recognition and electrochemical amplification properties, the chip fabrication for magnetic gradient ranking and electrochemical sensing, and the final integration of the POC platform for cancer biomarker diagnosis. The device detection sensitivity will be in ng/ml range with an estimated duration of 15 min for each test from blood serum.

Objective

Breast cancer is the most common neoplasm in women and the second leading cause of cancer-related mortality in females worldwide, with 25.1% of incidence and 14.7% of mortality across all cancers. A convenient blood-based tumor marker test has the potential to underpin a significant improvement in early intervention.
In this context, this proposal is concerned with development of a new point of care (POC) device for biomarker detection by exploiting a combination of state of the art magnetophoresis, electroanalysis, nanotechnology, and microfluidic integration. In the POC device, dual-functionalized magnetic nanoparticles (dual-NPs) with antibodies and redox probes will be capable of selectively recruiting specific markers from real patient samples and will additionally underpin amplified redox probes for detection. Second, using a magnetic gradient chip, composed of both magnetic gradient (Mag) and microelectrode (Me) arrays, the exerted magnetic gradient field will be capable of separating dual-NPs labeling biomarkers (MBs) from free dual-NPs (MPs) to be positioned at distinct sensing zone of micro-electrode, prior to assay. Herein, only those biomarkers hosted by dual-NPs, will be reported electrochemically for quantification.
Three primary objectives are proposed by the candidate: i) development of dual-NPs combining immunological recognition and electrochemical amplification properties, ii) fabrication of Mag chip engineering Mag and Me arrays for magnetic gradient ranking and electrochemical sensing, iii) integration of POC platform with Mag and Me arrays, dual-NPs and microchannels, for cancer biomarker diagnosis.
As a proof-of-concept, the developed POC device will be applied to the detection and quantification of breast cancer markers (CA15-3, PAI-1 and HSP90A) in a small (<20µL) blood serum. The detection limit of this device is expected to be ng/ml quantities and duration is estimated to 15 mins for each test with blood serum.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF-EF-ST - Standard EF

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Net EU contribution
€ 184 590,72
Address
BELFIELD
4 Dublin
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 184 590,72